Literature DB >> 23632268

A risk stratification model of acute pyelonephritis to indicate hospital admission from the ED.

Changwoo Kang1, Kyuseok Kim, Soo Hoon Lee, Chanjong Park, Joonghee Kim, Jae Hyuk Lee, You Hwan Jo, Joong Eui Rhee, Dong Hoon Kim, Seong Chun Kim.   

Abstract

OBJECTIVES: There are no guidelines regarding the hospitalization of female patients with acute pyelonephritis (APN); therefore, we performed a retrospective analysis to construct a clinical prediction model for hospital admission.
METHODS: We conducted a retrospective analysis of a prospective database of women diagnosed as having APN in the emergency department between January 2006 and June 2012. Independent risk factors for admission were determined by multivariable logistic regression analysis in half of the patients in this database. The risk of admission was categorized into 5 groups. The internal and external validations were conducted using the remaining half of the patients and 192 independent patients, respectively.
RESULTS: Independent risk factors for admission were age of 65 years or greater (odds ratio [OR], 2.62; 1 point), chill (OR, 2.40; 1 point), and the levels of segmented neutrophils greater than 90% (OR, 2.00; 1 point), serum creatinine greater than 1.5 mg/dL (OR, 2.41; 1 point), C-reactive protein greater than 10 mg/dL (OR, 2.37; 1 point), and serum albumin less than 3.3 g/dL (OR, 7.36; 2 points). The admission risk scores consisted of 5 categories, which were very low (0 points; 5.9%), low (1 point; 10.7%), intermediate (2 points; 20.7%), high (3-4 points; 51.9%), and very high (5-7 points; 82.8%) risk, showing an area under the curve of 0.770. The areas under the curve of the internal and external validation cohorts were 0.743 and 0.725, respectively.
CONCLUSION: This model can provide a guideline to determine the admission of women with APN in the emergency department.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23632268     DOI: 10.1016/j.ajem.2013.03.048

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  5 in total

1.  Predictors of ultrasound abnormalities among women treated for community-onset acute pyelonephritis: a prospective study.

Authors:  Franck Bruyère; Yoann Conan; Maxime Vallée; Christophe Gaborit; Hugo Crespin; Joseph-Alain Ruimy; Albert Sotto; Leslie Grammatico-Guillon
Journal:  World J Urol       Date:  2022-09-02       Impact factor: 3.661

2.  Clinical and computed tomography factors associated with sepsis in women with clinically uncomplicated pyelonephritis.

Authors:  Young Rock Jang; Su Joa Ahn; Seung Joon Choi; Joong Sik Eom; Yong Kyun Cho; Young Sup Shim; So Hyun Park; Jeong Ho Kim; Hyung-Sik Kim
Journal:  Abdom Radiol (NY)       Date:  2020-08-28

3.  Vomiting and Hyponatremia Are Risk Factors for Worse Clinical Outcomes Among Patients Hospitalized Due to Nonsurgical Abdominal Pain: A Retrospective Cohort Study.

Authors:  Idan Goren; Ariel Israel; Narin N Carmel-Neiderman; Iris Kliers; Irina Gringauz; Amir Dagan; Bruno Lavi; Omer Segal; Gad Segal
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

4.  Hospitalization for community-acquired febrile urinary tract infection: validation and impact assessment of a clinical prediction rule.

Authors:  Janneke E Stalenhoef; Willize E van der Starre; Albert M Vollaard; Ewout W Steyerberg; Nathalie M Delfos; Eliane M S Leyten; Ted Koster; Hans C Ablij; Jan W Van't Wout; Jaap T van Dissel; Cees van Nieuwkoop
Journal:  BMC Infect Dis       Date:  2017-06-06       Impact factor: 3.090

5.  Clinical and epidemiological features and prognosis of complicated pyelonephritis: a prospective observational single hospital-based study.

Authors:  Veronica A Buonaiuto; Ignacio Marquez; Inmaculada De Toro; Carolina Joya; Juan D Ruiz-Mesa; Raimundo Seara; Antonio Plata; Beatriz Sobrino; Begoña Palop; Juan D Colmenero
Journal:  BMC Infect Dis       Date:  2014-12-10       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.